NIH tells grant reviewers how to ensure alignment with Trump
Signaling a move toward the next phase of change, leaders at the National Institutes of Health have sent new guidance to its staff on how to further move its $39 billion portfolio in alignment with the Trump administration’s priorities. The seven-page guidance, sent on Friday and titled “Reviewing Grants for Priority Alignment,” provides details to […]
At AHRQ, cuts undermine federal research on how to improve health care
WASHINGTON — A small federal agency that studies how to improve the health care system has been rendered functionally “incapacitated” after much of its staff was laid off or retired, according to three people, including two former employees, who spoke with STAT. The loss of most of the workers at the Agency for Healthcare Research […]
How to think about Trump’s pharma tariffs — before they hit
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. For weeks, President Trump has made it clear that tariffs are going to be slapped on pharmaceuticals. But that is about the only thing that is clear. For the moment, his administration has opened a […]
Buy them and shut them down
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Health care investor Kevin Tang buys “zombie” biotechs to shut them down. It’s a counterintuitive, but ingenious solution to the sector’s intractable problem covered in last week’s newsletter. Tang’s disposal service is not a […]
Gilead needs a win with Arcellx CAR-T data. Here’s how to know if it scores
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching. Circle Nov. 5 on your calendars. That’s when we’ll get the first look at data from a pivotal clinical trial of anito-cel, […]